Literature DB >> 32296841

In vitro modeling of glioblastoma initiation using PDGF-AA and p53-null neural progenitors.

Alexandra K Bohm1,2, Jessica DePetro1,2, Carmen E Binding1,2, Amanda Gerber1,2, Nicholas Chahley1,2, N Dan Berger1,2, Mathaeus Ware1,2, Kaitlin Thomas1,2, U Senapathi1,2, Shazreh Bukhari1,2, Cindy Chen1,2, Erin Chahley1,2, Cameron Grisdale3, Sam Lawn1,2, Yaping Yu2, Raymond Wong4, Yaoqing Shen5, Hiba Omairi1,2, Reza Mirzaei1,3, Nourah Alshatti1,2, Haley Pedersen1,2, Wee Yong1,2,3, Samuel Weiss1,2,3, Jennifer Chan1,2,3, P J Cimino6, John Kelly1,2,3, Steve Jones5, Eric Holland6, Michael Blough1,2, Gregory Cairncross1,2,5.   

Abstract

BACKGROUND: Imagining ways to prevent or treat glioblastoma (GBM) has been hindered by a lack of understanding of its pathogenesis. Although overexpression of platelet derived growth factor with two A-chains (PDGF-AA) may be an early event, critical details of the core biology of GBM are lacking. For example, existing PDGF-driven models replicate its microscopic appearance, but not its genomic architecture. Here we report a model that overcomes this barrier to authenticity.
METHODS: Using a method developed to establish neural stem cell cultures, we investigated the effects of PDGF-AA on subventricular zone (SVZ) cells, one of the putative cells of origin of GBM. We microdissected SVZ tissue from p53-null and wild-type adult mice, cultured cells in media supplemented with PDGF-AA, and assessed cell viability, proliferation, genome stability, and tumorigenicity.
RESULTS: Counterintuitive to its canonical role as a growth factor, we observed abrupt and massive cell death in PDGF-AA: wild-type cells did not survive, whereas a small fraction of null cells evaded apoptosis. Surviving null cells displayed attenuated proliferation accompanied by whole chromosome gains and losses. After approximately 100 days in PDGF-AA, cells suddenly proliferated rapidly, acquired growth factor independence, and became tumorigenic in immune-competent mice. Transformed cells had an oligodendrocyte precursor-like lineage marker profile, were resistant to platelet derived growth factor receptor alpha inhibition, and harbored highly abnormal karyotypes similar to human GBM.
CONCLUSION: This model associates genome instability in neural progenitor cells with chronic exposure to PDGF-AA and is the first to approximate the genomic landscape of human GBM and the first in which the earliest phases of the disease can be studied directly.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  GBM; PDGF-AA; genome instability; glioblastoma; model; p53

Mesh:

Substances:

Year:  2020        PMID: 32296841      PMCID: PMC7594559          DOI: 10.1093/neuonc/noaa093

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  26 in total

1.  Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system.

Authors:  B A Reynolds; S Weiss
Journal:  Science       Date:  1992-03-27       Impact factor: 47.728

2.  Genomic instability during reprogramming by nuclear transfer is DNA replication dependent.

Authors:  Gloryn Chia; Judith Agudo; Nathan Treff; Mark V Sauer; David Billing; Brian D Brown; Richard Baer; Dieter Egli
Journal:  Nat Cell Biol       Date:  2017-03-06       Impact factor: 28.824

3.  Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma.

Authors:  Tatsuya Ozawa; Markus Riester; Yu-Kang Cheng; Jason T Huse; Massimo Squatrito; Karim Helmy; Nikki Charles; Franziska Michor; Eric C Holland
Journal:  Cancer Cell       Date:  2014-08-11       Impact factor: 31.743

4.  Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis.

Authors:  Verena Körber; Jing Yang; Pankaj Barah; Yonghe Wu; Damian Stichel; Zuguang Gu; Michael Nai Chung Fletcher; David Jones; Bettina Hentschel; Katrin Lamszus; Jörg Christian Tonn; Gabriele Schackert; Michael Sabel; Jörg Felsberg; Angela Zacher; Kerstin Kaulich; Daniel Hübschmann; Christel Herold-Mende; Andreas von Deimling; Michael Weller; Bernhard Radlwimmer; Matthias Schlesner; Guido Reifenberger; Thomas Höfer; Peter Lichter
Journal:  Cancer Cell       Date:  2019-03-21       Impact factor: 31.743

5.  Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.

Authors:  Evangelia Razis; Panayotis Selviaridis; Stephanos Labropoulos; Jeremy L Norris; Mei-Jun Zhu; David D Song; Thea Kalebic; Michael Torrens; Anna Kalogera-Fountzila; George Karkavelas; Sofia Karanastasi; Jonathan A Fletcher; George Fountzilas
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

6.  CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.

Authors:  K Ueki; Y Ono; J W Henson; J T Efird; A von Deimling; D N Louis
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

7.  Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.

Authors:  John J P Kelly; Owen Stechishin; Andrew Chojnacki; Xueqing Lun; Beichen Sun; Donna L Senger; Peter Forsyth; Roland N Auer; Jeff F Dunn; J Gregory Cairncross; Ian F Parney; Samuel Weiss
Journal:  Stem Cells       Date:  2009-08       Impact factor: 6.277

8.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.

Authors:  Michele Ceccarelli; Floris P Barthel; Tathiane M Malta; Thais S Sabedot; Sofie R Salama; Bradley A Murray; Olena Morozova; Yulia Newton; Amie Radenbaugh; Stefano M Pagnotta; Samreen Anjum; Jiguang Wang; Ganiraju Manyam; Pietro Zoppoli; Shiyun Ling; Arjun A Rao; Mia Grifford; Andrew D Cherniack; Hailei Zhang; Laila Poisson; Carlos Gilberto Carlotti; Daniela Pretti da Cunha Tirapelli; Arvind Rao; Tom Mikkelsen; Ching C Lau; W K Alfred Yung; Raul Rabadan; Jason Huse; Daniel J Brat; Norman L Lehman; Jill S Barnholtz-Sloan; Siyuan Zheng; Kenneth Hess; Ganesh Rao; Matthew Meyerson; Rameen Beroukhim; Lee Cooper; Rehan Akbani; Margaret Wrensch; David Haussler; Kenneth D Aldape; Peter W Laird; David H Gutmann; Houtan Noushmehr; Antonio Iavarone; Roel G W Verhaak
Journal:  Cell       Date:  2016-01-28       Impact factor: 41.582

9.  A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine.

Authors:  Hyun Jung Jun; Vicky A Appleman; Hua-Jun Wu; Christopher M Rose; Javier J Pineda; Alan T Yeo; Bethany Delcuze; Charlotte Lee; Aron Gyuris; Haihao Zhu; Steve Woolfenden; Agnieszka Bronisz; Ichiro Nakano; Ennio A Chiocca; Roderick T Bronson; Keith L Ligon; Jann N Sarkaria; Steve P Gygi; Franziska Michor; Timothy J Mitchison; Al Charest
Journal:  Nat Commun       Date:  2018-08-06       Impact factor: 14.919

10.  MicroRNA-7-5p induces cell growth inhibition, cell cycle arrest and apoptosis by targeting PAK2 in non-small cell lung cancer.

Authors:  Qin Li; Xingping Wu; Lin Guo; Jiaxin Shi; Jiashu Li
Journal:  FEBS Open Bio       Date:  2019-10-24       Impact factor: 2.693

View more
  4 in total

1.  High replication stress and limited Rad51-mediated DNA repair capacity, but not oxidative stress, underlie oligodendrocyte precursor cell radiosensitivity.

Authors:  N Daniel Berger; Peter M Brownlee; Myra J Chen; Hali Morrison; Katalin Osz; Nicolas P Ploquin; Jennifer A Chan; Aaron A Goodarzi
Journal:  NAR Cancer       Date:  2022-04-12

Review 2.  Adamantinomatous craniopharyngioma as a model to understand paracrine and senescence-induced tumourigenesis.

Authors:  Jose Mario Gonzalez-Meljem; Juan Pedro Martinez-Barbera
Journal:  Cell Mol Life Sci       Date:  2021-03-26       Impact factor: 9.261

3.  In the beginning: PDGFA and the genesis of GBM.

Authors:  Michael D Blough; Mehul Kumar; Pinaki Bose; J Gregory Cairncross
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

4.  The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin.

Authors:  Gong Peng; Yin Wang; Pengfei Ge; Christopher Bailey; Peng Zhang; Di Zhang; Zhaoli Meng; Chong Qi; Qian Chen; Jingtao Chen; Junqi Niu; Pan Zheng; Yang Liu; Yan Liu
Journal:  J Exp Clin Cancer Res       Date:  2021-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.